Optinose (id:8237 OPTN)
0.395 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 1:43:31 AM)
Exchange closed, opens in 7 hours 46 minutes
About Optinose
Market Capitalization 58.07M
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Headquarters (address) |
1020 Stony Hill Road Yardley 19067 PA United States |
| Phone | 267 364 3500 |
| Website | https://www.optinose.com |
| Employees | 132 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | OPTN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.321 - 2.10 |
| Market Capitalization | 58.07M |
| P/E trailing | -1.15 |
| P/E forward | -4.28 |
| Price/Sale | 0.767 |
| Price/Book | -1.56 |
| Beta | -0.068 |
| EPS | -0.340 |
| EPS United States (ID:6, base:3394) | 24.31 |